Nomura Holdings’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-25,124
| Closed | -$967K | – | 1724 |
|
|
2024
Q2 | $967K | Buy |
+25,124
| New | +$1.06M | ﹤0.01% | 1161 |
|
|
2024
Q1 | – | Sell |
-118,834
| Closed | -$4.4M | – | 1788 |
|
|
2023
Q4 | $4.4M | Buy |
118,834
+33,979
| +40% | +$1.22M | 0.01% | 706 |
|
|
2023
Q3 | $3.08M | Sell |
84,855
-1,279,764
| -94% | -$45.4M | 0.01% | 685 |
|
|
2023
Q2 | $48.6M | Sell |
1,364,619
-96,619
| -7% | -$3.47M | 0.13% | 123 |
|
|
2023
Q1 | $52M | Sell |
1,461,238
-622,780
| -30% | -$21.8M | 0.17% | 106 |
|
|
2022
Q4 | $73.2M | Buy |
+2,084,018
| New | +$69.4M | 0.3% | 73 |
|
|
2022
Q3 | – | Sell |
-2,577,897
| Closed | -$141M | – | 1805 |
|
|
2022
Q2 | $141M | Buy |
2,577,897
+1,028,955
| +66% | +$56.8M | 0.49% | 33 |
|
|
2022
Q1 | $84.6M | Sell |
1,548,942
-1,957,625
| -56% | -$106M | 0.25% | 52 |
|
|
2021
Q4 | $193M | Buy |
3,506,567
+3,356,637
| +2,239% | +$175M | 0.49% | 31 |
|
|
2021
Q3 | $7.18M | Sell |
149,930
-3,078,054
| -95% | -$155M | 0.02% | 509 |
|
|
2021
Q2 | $161M | Buy |
3,227,984
+487,635
| +18% | +$23.4M | 0.41% | 39 |
|
|
2021
Q1 | $125M | Buy |
2,740,349
+2,732,816
| +36,278% | +$124M | 0.28% | 48 |
|
|
2020
Q4 | $348K | Sell |
7,533
-8,166
| -52% | -$375K | ﹤0.01% | 1298 |
|
|
2020
Q3 | $738K | Buy |
+15,699
| New | +$787K | ﹤0.01% | 898 |
|
|
2018
Q3 | – | Sell |
-5,327
| Closed | -$233K | – | 1380 |
|
|
2018
Q2 | $233K | Sell |
5,327
-25,482
| -83% | -$1.28M | ﹤0.01% | 1167 |
|
|
2018
Q1 | $1.5K | Buy |
30,809
+2,474
| +9% | +$115K | ﹤0.01% | 940 |
|
|
2017
Q4 | $1.25M | Sell |
28,335
-8,871
| -24% | -$410K | ﹤0.01% | 1041 |
|
|
2017
Q3 | $1.89M | Buy |
37,206
+32,292
| +657% | +$1.64M | ﹤0.01% | 868 |
|
|
2017
Q2 | $265K | Buy |
+4,914
| New | +$262K | ﹤0.01% | 1351 |
|
|
2016
Q1 | – | Sell |
-6,002
| Closed | -$303K | – | 1722 |
|
|
2015
Q4 | $303K | Buy |
+6,002
| New | +$306K | ﹤0.01% | 1306 |
|
|
2014
Q4 | – | Sell |
-7,757
| Closed | -$434K | – | 2454 |
|
|
2014
Q3 | $446K | Buy |
7,757
+5,974
| +335% | +$366K | ﹤0.01% | 1905 |
|
|
2014
Q2 | $119K | Sell |
1,783
-1,059
| -37% | -$71.7K | ﹤0.01% | 2502 |
|
|
2014
Q1 | $191K | Sell |
2,842
-973
| -26% | -$65.8K | ﹤0.01% | 2360 |
|
|
2013
Q4 | $254K | Sell |
3,815
-1,895
| -33% | -$123K | ﹤0.01% | 1633 |
|
|
2013
Q3 | $359K | Sell |
5,710
-18,801
| -77% | -$1.21M | ﹤0.01% | 1573 |
|
|
2013
Q2 | $1.54M | Buy |
+24,511
| New | +$1.56M | 0.01% | 799 |
|
Other funds holding GSK
JEST
Nomura Holdings's GSK Position: Q3 2024 in Review
Nomura Holdings sold out of GSK (GSK) in Q3 2024, closing a stake of 25,124 shares — an estimated $967K sold.
Nomura Holdings first reported a position in GSK in Q2 2013 and held it in 26 quarters. The position peaked at $193M in Q4 2021. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.
- Nomura Holdings reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
- Nomura Holdings sold 25,124 GSK shares in Q3 2024, an estimated $967K.
- Nomura Holdings first reported a position in GSK in Q2 2013 and held it in 26 quarters.
- Nomura Holdings's GSK position peaked at $193M in Q4 2021.
- 899 funds tracked by Wall St. Rank held GSK as of Q3 2024.
Based on Nomura Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.